BioArts International, a biotech company in the San Francisco area, has discontinued its commercial dog cloning services. As such, the company has also ended its partnership with South Korean cloning vendor Sooam Biotech Research Foundation and its head Dr. Hwang Woo-Suk.
The fifth and final set of cloned dogs was delivered in September.
Lou Hawthorne, chief executive officer, cited a list of reasons why the company made its decision, a tiny market being one of them. […]
Hawthorne also blamed black market competition. A company that would offer the same services would be in violation of international patents, he said, because BioArts holds the sole, worldwide rights to clone dogs, cats and endangered species.
For instance, a South Korean biotech company advertised in February 2008 that it would clone dogs at a fraction of BioArts’ price, starting at $150,000 and then down to $30,000.